EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Absorption pharmacokinetics and feasibility of intranasal dexmedetomidine in patients under general anaesthesia

Suvi-Maria Tiainen iD, Brian J Anderson iD, Ella Rinne, Aleksi Tornio iD, Marica T Engström iD, Teijo I Saari iD, Panu Uusalo iD

Acta Anaesthesiologica Scandinavica · 2024-10 · 68 (9) · 1182-1191

DOI: 10.1111/aas.14473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Anaesthesiologica Scandinavica, online erschienen am 19.06.2024. Verfasst von Suvi-Maria Tiainen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland. Hauptthemen laut MEDLINE: Dexmedetomidine, Administration, Intranasal, Anesthesia, General, Feasibility Studies. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Emil Aaltonen foundation, EVO grant from Satasairaala Central Hospital, EVO grant from Turku University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of intranasal dexmedetomidine is hampered by a limited understanding of its absorption pharmacokinetics.

Methods

We examined the pharmacokinetics and feasibility of intranasal dexmedetomidine administered in the supine position to adult patients undergoing general anaesthesia. Twenty‐eight patients between 35 and 80 years of age, ASA 1–3 and weight between 50 and 100 kg, who underwent elective unilateral total hip or knee arthroplasty under general anaesthesia were recruited. All patients received 100 μg of intranasal dexmedetomidine after anaesthesia induction. Six venous blood samples (at 0, 5, 15, 45, 60, 240 min timepoints from dexmedetomidine administration) were collected from each patient and dexmedetomidine plasma concentrations were measured. Concentration‐time profiles after nasal administration were pooled with earlier data from a population analysis of intravenous dexmedetomidine ( n = 202) in order to estimate absorption parameters using nonlinear mixed effects. Peak concentration ( C MAX ) and time ( T MAX ) were estimated using simulation ( n = 1000) with parameter estimates and their associated variability.

Results

There were 28 adult patients with a mean (SD) age of 66 (8) years and weight of 83 (10) kg. The mean weight‐adjusted dose of dexmedetomidine was 1.22 (0.15) μg kg −1 . C MAX 0.273 μg L −1 was achieved at 98 min after intranasal administration ( T MAX ). The relative bioavailability of dexmedetomidine was 80% (95% CI 75–91%). The absorption half‐time ( T ABS = 120 min; 95% CI 90–147 min) was slower than that in previous pharmacokinetic studies on adult patients. Perioperative haemodynamics of all patients remained stable.

Conclusions

Administration of intranasal dexmedetomidine in the supine position during general anaesthesia is feasible with good bioavailability. This administration method has slower absorption when compared to awake patients in upright position, with consequent concentrations attained after T MAX for several hours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineAdministration, IntranasalAnesthesia, GeneralFeasibility StudiesHypnotics and SedativesHumansAgedMaleMiddle AgedFemaleAdultAged, 80 and over

Stichwörter der Autor:innen

alpha2‐agonistsextravascular administrationintranasal administrationpharmacokinetics

Substanzen

DexmedetomidineHypnotics and Sedatives

Autor:innen und Institutionen

  • Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland.
  • Division of Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland.
  • Department of Anaesthesiology and Intensive Care, Satasairaala Central Hospital, Satakunta Hospital District, Pori, Finland.
  • Department of Anaesthesiology, University of Auckland, Auckland, New Zealand.
  • Medical faculty, University of Turku, Turku, Finland.
  • Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland.

ORCID-Profile: Suvi-Maria Tiainen, Brian J Anderson, Aleksi Tornio, Marica T Engström, Teijo I Saari, Panu Uusalo

Förderung

  • Emil Aaltonen foundation
  • EVO grant from Satasairaala Central Hospital
  • EVO grant from Turku University Hospital
  • Emil Aaltosen Säätiö

Zitieren

APA

Tiainen, S. M., Anderson, B. J., Rinne, E., Tornio, A., Engström, M. T., Saari, T. I., & Uusalo, P. (2024). Absorption pharmacokinetics and feasibility of intranasal dexmedetomidine in patients under general anaesthesia. Acta Anaesthesiologica Scandinavica, 68(9), 1182-1191. https://doi.org/10.1111/aas.14473

Vancouver

Tiainen SM, Anderson BJ, Rinne E, Tornio A, Engström MT, Saari TI, et al. Absorption pharmacokinetics and feasibility of intranasal dexmedetomidine in patients under general anaesthesia. Acta Anaesthesiologica Scandinavica. 2024;68(9):1182-1191. doi:10.1111/aas.14473

BibTeX
@article{Tiainen2024,
  author = {Tiainen, Suvi-Maria and Anderson, Brian J and Rinne, Ella and Tornio, Aleksi and Engström, Marica T and Saari, Teijo I and Uusalo, Panu},
  title = {Absorption pharmacokinetics and feasibility of intranasal dexmedetomidine in patients under general anaesthesia},
  journal = {Acta Anaesthesiologica Scandinavica},
  year = {2024},
  volume = {68},
  number = {9},
  pages = {1182--1191},
  doi = {10.1111/aas.14473}
}
Kostenlos starten →